Table 2 Description of HPV positive patients characteristics including viral load, gender, histology, performance status, stage of disease, survival days and treatment strategy. *genomes/human genome equivalents. **alive at follow up, censored in the survival analyze. Nd-the parameter could not be determined. Histology: ESCC-Squamous cell carcinoma, AC-Adenocarcinoma, MEC-Mucoepidermoid carcinoma. Treatment strategy: 1. Pre-operative concommitant chemoradiotherapy, 2. Curatively intended radiotherapy 2–60 Gy, 3. Palliative intended radiotherapy and chemotherapy, 4. Palliative care including chemotherapy.
HPV16 Viral load* | Gender | Histology | Performace status | Advanced disease | Survival days | Treatment strategy |
|---|---|---|---|---|---|---|
437,0 | Male | ESCC | 3 | No | 23 | 3 |
< 94 | Women | ESCC | 2 | Yes | 207 | 2 |
<31 | Male | ESCC | 1 | No | 98 | 3 |
27,3 | Male | ESCC | 2 | Yes | 30 | 4 |
<17 | Women | ESCC | 1 | No | 1569 | 2 |
15,7 | Women | ESCC | 1 | No | 626 | 3 |
6,6 | Male | ESCC | 0 | No | **1343 | 3 |
5,3 | Women | MEC | 0 | No | 650 | 2 |
3,3 | Male | ESCC | 0 | No | 1028 | 2 |
2,1 | Male | AC | 0 | Yes | 1870 | 4 |
0,6 | Male | AC | nd | No | 1854 | 3 |
0,6 | Women | AC | 3 | No | 73 | 4 |
0,5 | Male | ESCC | 0 | No | 492 | 1 |
0,2 | Male | AC | 0 | No | 934 | 2 |
0,2 | Women | AC | 1 | Yes | 168 | 4 |
0,1 | Male | ESCC | 3 | Yes | 6 | 4 |